News

Wound Healing and Exudate –⁠ A Comprehensive Look at Moisture Management in Wounds

14. 12. 2023 Source: Wound Healing

Exudate produced during the inflammatory phase of healing is a crucial factor that ensures a moist environment in the wound, provides nutrients for cellular metabolism, and supports autolytic debridement. Without proper exudate management and maintenance of optimal moisture in the wound, patients are exposed to a range of risks and complications in healing.

Effective antiosteoporotics from the aminobisphosphonate group can finally be prescribed by general practitioners from January 2024

Osteoporosis represents a serious societal problem generating numerous health and social complications as well as considerable economic costs. In the Czech Republic, it is estimated to affect 500−750…

12. 12. 2023 Source: Treatment of Osteoporosis

Augmentation of Clozapine with Lurasidone in Resistant Schizophrenia in Real Practice

Treatment-resistant schizophrenia remains a clinical and pharmacological challenge. Clozapine remains the gold standard in these cases. Unfortunately, a significant portion of patients respond only…

12. 12. 2023 Source: Modern Treatment of Schizophrenia

Criteria for Progression in Fibrotic Non-IPF Interstitial Lung Disease

Fibrotic interstitial lung disease (fILD) is a challenging condition to manage with limited therapeutic options and a poor prognosis. The currently published review analyzes the criteria for its…

11. 12. 2023 Source: Progressive Interstitial Pulmonary Processes

Selecting from the Red Book CHS: What's New in This Year's Recommendations for the Diagnosis and Treatment of CLL?

Chronic lymphocytic leukemia (CLL) is the most common lymphoid malignancy in adults in Europe and North America. However, this field is experiencing very dynamic developments, both in terms of…

7. 12. 2023 Source: Chronic Lymphocytic Leukemia

Lung screening in the Czech Republic has detected over a hundred cases of lung cancer

The purpose of lung screening, which has been ongoing in the Czech Republic since January 2022, is to detect early stages of lung cancer and increase awareness of this malignant disease in relation…

7. 12. 2023 Source: Respiratory Health

Safety of Tofacitinib in Ulcerative Colitis –⁠ Combined Results of 6 Studies

At the annual meeting of the American Gastroenterological Association (ACG) in October 2023 in Vancouver, Canada, the results of the final safety analysis of tofacitinib in the treatment of…

7. 12. 2023 Source: Intestinal Inflammations

Impact of Tofacitinib on the Quality of Life of Patients with Ulcerative Colitis

Tofacitinib is an oral Janus kinase (JAK) inhibitor used in the treatment of certain rheumatic diseases and ulcerative colitis (UC). The work presented at this year's 18th congress of the European…

7. 12. 2023 Source: Intestinal Inflammations

Use of Testosterone Level as a Biomarker for Quality of Life in Patients with Prostate Cancer

In the treatment of prostate cancer, in addition to surgical treatment, stereotactic body radiotherapy (SBRT) and hormone therapy are also used. Androgen deprivation therapy (ADT) blocks the action…

6. 12. 2023 Source: Oncological Treatment

How Does Empagliflozin Stand in Terms of Diabetic Retinopathy Risk? We Have Answers Not Only from Controlled Studies but Also from Real Practice

Modern antidiabetics –⁠ gliflozins and glucagon-like peptide-1 receptor agonists (GLP-1RA) –⁠ significantly help improve the management of type 2 diabetes (DM2). In addition to reliable glycemic…

5. 12. 2023 Source: Diabetes

The Significance of Administering Gliflozins in Real Practice in Diabetics Without CV and Renal Disease

Current care standards recommend the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) regardless of glycemic compensation in patients with type 2 diabetes (T2DM) and kidney…

5. 12. 2023 Source: Diabetes

Doc. Miloslav Salavec: We Still Encounter Delayed Initiation of Biological Treatment in AD and Many Other Diagnoses

Not all patients with atopic dermatitis (AD) who are indicated for biological treatment with dupilumab manage to reach centers where the treatment is provided. It's even more unfortunate when there's…

4. 12. 2023 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation

Dual Inhibition of IL-17A/IL-17F Across the Spectrum of Axial Spondyloarthritis

Many patients with axial spondyloarthritis (axSpA) still have a need to seek additional therapeutic options and new mechanisms of action for medicinal substances. Phase III studies BE MOBILE 1 and 2…

1. 12. 2023 Source: Rheumatic Diseases

Effectiveness and Safety of Initiating Treatment for Primary Immunodeficiency with Subcutaneously Administered Immunoglobulins –⁠ A Systematic Review of the Literature

The aim of the systematic review of the literature published last year was to evaluate the effectiveness and safety of initiating treatment with subcutaneously administered immunoglobulins (SCIG) in…

1. 12. 2023 Source: Primary and Secondary Immunodeficiencies

10 Warning Signs of Primary and Secondary Immunodeficiencies

The Jeffrey Modell Foundation (JMF) proposed 10 warning signs of primary immunodeficiencies (PID). The study presented below examined whether they are applicable to secondary immunodeficiencies (SID)…

1. 12. 2023 Source: Primary and Secondary Immunodeficiencies

1 … 16 17 18 19 20 … 114

Back Filter by speciality

Remove filters